Physicochemical Properties
| Molecular Formula | C24H23NO3F2 |
| Molecular Weight | 411.44112 |
| Exact Mass | 411.165 |
| CAS # | 939681-36-4 |
| PubChem CID | 146160226 |
| Appearance | Off-white to light yellow solid powder |
| LogP | 5.189 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 30 |
| Complexity | 666 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC(OC(=O)N1C/C(=C/C2=CC=CC=C2F)/C(=O)/C(=C\C3=CC=CC=C3F)/C1)(C)C |
| InChi Key | MCSPIRBNMDODQP-BKHHGCLFSA-N |
| InChi Code | InChI=1S/C24H23F2NO3/c1-24(2,3)30-23(29)27-14-18(12-16-8-4-6-10-20(16)25)22(28)19(15-27)13-17-9-5-7-11-21(17)26/h4-13H,14-15H2,1-3H3/b18-12-,19-13- |
| Chemical Name | tert-butyl (3Z,5Z)-3,5-bis[(2-fluorophenyl)methylidene]-4-oxopiperidine-1-carboxylate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | G5-7 (0-5 μM) stops the cell cycle in the G2 phase and suppresses downstream mTOR signaling and EGFR tyrosine phosphorylation [1]. G5-7 does not prevent EGFR activation directly [1]. In both parental LN229 cells and U87MG/EGFRvIII cells, G5-7 (0-10 μM) substantially raises the amount of apoptotic markers (cleaved PARP and caspase 3) [1]. G5-7 engages in interactions with JAK2 throughout its entirety [1]. While G5-7 has no effect on EGFR Tyr1045 phosphorylation, it strongly reduces EGFR Tyr1068 phosphorylation [1]. Through mTOR, G5-7 suppresses downstream signaling from JAK [1]. |
| ln Vivo | Oral G5-7 (10 and 50 mg/kg) has strong anti-angiogenic properties and decreases VEGF secretion [1]. |
| Cell Assay |
Western blot analysis[1]. Cell Types: U87MG/PTEN cells. Tested Concentrations: 0-5μM. Incubation Duration: 6 hrs (hours). Experimental Results: Blocked EGFR phosphorylation and G2 phase cell cycle, inhibiting cell proliferation. |
| Animal Protocol |
Animal/Disease Models: Cells (4 × 106) in 100 μl serum-free DMEM were inoculated subcutaneously (sc) (sc) into 5- to 6weeks old female nude mice [1]. Doses: 10 and 50 mg/kg. Route of Administration: po (oral gavage). Experimental Results: Inhibition of angiogenesis in tumors. |
| References |
[1]. Blockade of glioma proliferation through allosteric inhibition of JAK2. Sci Signal. 2013 Jul 9;6(283):ra55. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~83.33 mg/mL (~217.35 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4305 mL | 12.1524 mL | 24.3049 mL | |
| 5 mM | 0.4861 mL | 2.4305 mL | 4.8610 mL | |
| 10 mM | 0.2430 mL | 1.2152 mL | 2.4305 mL |